E
Eija Kellokoski
Researcher at University of Oulu
Publications - 6
Citations - 784
Eija Kellokoski is an academic researcher from University of Oulu. The author has contributed to research in topics: Ghrelin & Type 2 diabetes. The author has an hindex of 6, co-authored 6 publications receiving 739 citations. Previous affiliations of Eija Kellokoski include Oulu University Hospital.
Papers
More filters
Journal ArticleDOI
Low Plasma Ghrelin Is Associated With Insulin Resistance, Hypertension, and the Prevalence of Type 2 Diabetes
TL;DR: It is concluded that low ghrelin is independently associated with type 2 diabetes, insulin concentration, insulin resistance, and elevated BP, and might have some role in the etiology of type 1 diabetes and the regulation of BP.
Journal ArticleDOI
Estrogen replacement therapy increases plasma ghrelin levels.
Eija Kellokoski,Seppo M. Pöykkö,Anna Karjalainen,Olavi Ukkola,Jorma Heikkinen,Y. Antero Kesäniemi,Sohvi Hörkkö +6 more
TL;DR: Investigation of the effects of estrogen replacement therapy on plasma active ghrelin levels in 64 hysterectomized postmenopausal women receiving peroral estrogen (PE) or transdermal estrogen therapy for 6 months concluded that estrogen replacement Therapy increased active plasma ghrelIn levels, particularly PE therapy.
Journal ArticleDOI
Plasma ghrelin concentrations are positively associated with carotid artery atherosclerosis in males.
Seppo M. Pöykkö,Eija Kellokoski,Olavi Ukkola,Heikki Kauma,Markku Päivänsalo,Y. A. Kesäniemi,Sohvi Hörkkö +6 more
TL;DR: The association between ghrelin concentration and carotid artery intima‐media thickness (IMT) in a population‐based cohort of 1024 middle‐aged (40–60 years) men and women is characterized.
Journal ArticleDOI
The negative association between plasma ghrelin and IGF-I is modified by obesity, insulin resistance and type 2 diabetes
TL;DR: There is a negative and independent association between ghrelin and IGF-I concentrations in middle-aged subjects and the interaction between IGF-i and gh Relin is modified by obesity, IR and type 2 diabetes.
Journal ArticleDOI
Ghrelin and obestatin modulate early atherogenic processes on cells: enhancement of monocyte adhesion and oxidized low-density lipoprotein binding
TL;DR: 3 lines of in vitro evidence supporting proatherogenic properties of ghrelin in the early stages of the disease are found, suggesting that ghrel in may also have an anti-inflammatory role in the presence of increased inflammation, for example, during the more progressed phases of atherogenesis.